Lygos closes $15.5M Series B round

Lygos closes $15.5M Series B round

The funds will accelerate commercialization of pipelined products and expand Lygos’s technology platform.

Diassess wins $21.9M federal contract for home flu test

Diassess wins $21.9M federal contract for home flu test

The funding will take home & clinical tests through clinical trials and submissions for FDA clearance.

Lygos a winner of inaugural "Consider Corn" Challenge

Lygos a winner of inaugural "Consider Corn" Challenge

The competition spotlights technology to convert corn into bio-renewable chemicals.

ViewPoint Therapeutics Raises $35 Million Series B

ViewPoint Therapeutics Raises $35 Million Series B

ViewPoint's technology prevents and treats cataracts and presbyopia.

QB3's "Pop-Up Institutes" Efficient Way to Tackle Big Challenges

QB3's "Pop-Up Institutes" Efficient Way to Tackle Big Challenges

Our pop-up institute on fibrosis convenes April 26 at UCSF.

QB3@953 changes name to "MBC Biolabs"

QB3@953 changes name to "MBC Biolabs"

The successful QB3 spinout is making the name change as part of a rebranding and expansion.

Zenflow raises $31M

Zenflow raises $31M

Zenflow's technology relieves urinary blockage caused by enlarged prostate. The funding will accelerate progress to market.

Silver Creek Pharmaceuticals Raises up to $20 Million Financing

Silver Creek Pharmaceuticals Raises up to $20 Million Financing

The financing will help the company advance its Smart Growth Factor™ pipeline into the clinic.

Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist

Carmot Therapeutics bags $15M for GLP-1R/GIPR agonist

This will take Carmot's lead Type 2 diabetes drug through clinical proof of concept.

Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR-T Footprint

Gilead, Kite to Acquire Cell Design Labs for Up-to-$567M, Growing CAR-T Footprint

Gilead reasons that the companies could treat a broader range of blood and solid cancers.